Click on the links below to view abstracts and posters presented at this congress. All copyright remains that of the copyright holder. This page will be available for a limited period after the congress.
Oral presentations
Tuesday 17 September 2019
OP 03 Addressing limitations of insulin therapy Ochoa Hall
OP 09 Semaglutide: ingested or injected Ochoa Hall
11:15 AM–11:30 AM
Oral presentation 17 Lane
Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both with insulin degludec with or without metformin, in adults with type 2 diabetes
View PDF
2:30 PM–2:45 PM
Oral presentation 49 Haluzík
Efficacy of oral semaglutide according to diabetes duration: an exploratory subgroup analysis of the PIONEER trial programme
View PDF
2:45 PM–3:00 PM
Oral presentation 50 Dahl
Oral semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with type 2 diabetes
View PDF
3:00 PM–3:15 PM
Oral presentation 51 Meier
Efficacy of oral semaglutide according to baseline HbA1c: an exploratory subgroup analysis of the PIONEER trial programmee
View PDF
3:15 PM–3:30 PM
Oral presentation 52 Lingvay
Once-weekly semaglutide vs. canagliflozin in type 2 diabetes: results of the SUSTAIN 8 trial
View PDF
3:30 PM–3:45 PM
Oral presentation 54 McCrimmon
Effects of once-weekly semaglutide vs. canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 trial
View PDF
3:45 PM–4:00 PM
Oral presentation 53 Capehorn
Efficacy and safety of semaglutide 1.0 mg once weekly vs. liraglutide 1.2 mg once daily as add-on to 1–3 oral glucose-lowering drugs in subjects with type 2 diabetes (SUSTAIN 10)
View PDF